Fig. 4: Potential predictive biomarkers of treatment efficacy. | Cell Research

Fig. 4: Potential predictive biomarkers of treatment efficacy.

From: Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial

Fig. 4

a A sketch map showing the subtype-based comprehensive study of FUSCC TNBC precision medicine. b Genomic landscape of refractory TNBC patients. c An exploratory forest plot of PFS in each arm and genes significantly affecting PFS are shown. Somatic mutations significantly affecting PFS were found only in arms C and E. Specific somatic mutations and unstratified hazard ratios with 95% CIs for PFS were obtained by univariate Cox hazard analysis. FUSCC Fudan University Shanghai Cancer Center, TNBC triple-negative breast cancer, LAR luminal androgen receptor, IM immunomodulatory, BLIS basal-like immunesuppressed, MES mesenchymal-like, CR complete response, PR partial response, SD stable disease, PD progressive disease, PFS progressionfree survival, HR hazard ratios, CI confidence interval, WT wild-type, MT mutation.

Back to article page